PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “ERYTHROPOIESIS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 973 records · Page 54Linked to original sources

Late afternoon administration of melatonin is prosomatotrophic and exerts androgen independent effects on erythropoiesis in male house sparrow Passer domesticus.

In the third week of September 1989, birds were purchased locally and acclimated to their housing conditions in a room fully exposed to natural day length (average: 11.96 hr) and temperature (26 degrees +/- 2 degrees C) for 2 weeks. Birds were in the regressive phase of their annual gonadal cycle. In the first experiment 24 birds were selected randomly and were divided into 3 groups of 8 birds each. Initial body weight and bill color score were recorded. The birds of group-I and group-II were injected daily with 5 and 10 micrograms of melatonin in 0.1 ml of vehicle, respectively. The birds of group-III were injected with vehicle only and treated as control. Injections were given daily between 1700 and 1730 hrs over a period of 10 days. At the termination of the experiment, the birds were weighed, sacrificed, bill color scored, blood collected and immediately processed to determine the number of erythrocytes and hemoglobin concentration. The mean body weight loss amounted to 9.6% in vehicle-treated house sparrow. Birds receiving low and high doses of melatonin maintained their initial body weight. Melatonin significantly accelerated the rate of bleaching of bill color. Results clearly indicate that in house sparrow, melatonin produces prosomatotrophic and antigonadotrophic effects. The low dose of melatonin stimulated erythropoiesis significantly. In the second experiment, melatonin nullified the castration-induced decline in the number of circulating red cells. This clearly suggests that the influence of melatonin on erythropoietic machinery appears to be independent of testicular hormone(s).

Animals↗

[Effect erythropoietin-beta on parameters of erythropoiesis and immunity in patients with diabetes mellitus complicated with diabetic neuropathy and anemia].

Erythropoiesis indices, number of leucocytes in 1 ml of blood, leukocytic formula, lymphocytes immunophenotype in the patients' blood with diabetes mellitus complicated with diabetic neuropathy and marked normochromal anemia after the treatment with Erythropoietin b have been analyzed in the study. Significant increase in haemoglobin, erythrocytes content, hematocrit indices of peripheral blood has been observed during the treatment. The patients felt better, their quality of life improved, CD3+, CD4+, CD5+ cells and granule-contained lymphocytes content normalized. Serious adverse affects of the medication haven't been observed in the study.

Adult↗

[Hypoxia involvement in erythropoiesis regulation--a new insight].

Oxygen, carried mainly by erythrocytes, plays a crucial role in human organisms--as the terminal electron acceptor enables mitochondria functioning and energy production. Oxygen excess may be a cause of the damage of basic structural organism components--proteins, lipids and nucleinic acids. Thus, from the biological point of view, regulation of oxygen supply with its detection mechanisms is a critical process. Erythrocyte content optima-lization, in means of "benefit-loss" is a compromise between the necessity of anaerobic metabolism transit (in case of too low erythrocyte count), excessive increase in blood viscosity and non-productive, increased red blood cell turn-over with increased erythrocyte level. It is in fact a process of adaptation to changeable environmental conditions, life style and possible pathological processes. The study is a review of knowledge on the oxygen sensor and its connection to erythropoiesis regulation.

Adenosine Triphosphate↗

CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia.

Anemia is a common and debilitating condition in patients with chronic kidney disease and patients with cancer. Over the last 10 to 15 years, the introduction of erythropoietic therapy has transformed the management of anemia in both these conditions. The first therapeutic agent to be used for the stimulation of erythropoiesis was recombinant human erythropoietin (epoetin). At the turn of this century, darbepoetin alfa, a second-generation erythropoietic agent, became available. Darbepoetin alfa contains two additional N-linked carbohydrate chains, which confer greater metabolic stability in vivo. More recently, a third-generation molecule, Continuous Erythropoietin Receptor Activator (CERA), incorporating a large polymer chain, has been developed. CERA has an elimination half-life in humans that is considerably longer than the half-life of either epoetin or darbepoetin alfa. CERA may also have different receptor binding characteristics and pharmacology from other erythropoietic agents; these characteristics are the subject of ongoing investigation. CERA is currently in phase III clinical trials.

Adolescent↗

Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts.

The expression of proteins of the tumor necrosis factor (TNF) family on erythroblasts was measured during thalidomide treatment in 29 patients with multiple myeloma (MM). A clinical response was observed in 17 patients (58.6%) and haemoglobin concentration increased in 22 patients (75.9%). The expression of FasL, Fas, TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL-R1 on erythroblasts decreased significantly during thalidomide treatment. Additional in vitro studies revealed that the apoptosis of erythroblasts and the expression of FasL, TRAIL, TRAIL-R1 and TRAIL-R2 was lower in cultures with thalidomide than in control cultures. Altogether our results suggest that thalidomide may stimulate erythropoiesis in MM patients by decreasing the expression of TNF-like ligands/receptors on erythroblasts.

Adult↗

Effects of blood withdrawal and reinfusion on biomarkers of erythropoiesis in humans: Implications for anti-doping strategies.

To discriminate autologous blood doping procedures from normal conditions, we examined the hematological response to blood withdrawal and reinfusion. We found that biomarkers of erythropoiesis are primarily affected in the anemic period. Therefore, individual variations in [Hb] exceeding 15% between samples obtained shortly before any major competition would be indicative of autologous blood manipulation.

Biomarkers↗

Erythropoiesis-stimulating protein support and survival.

Anemia is common in many patients with cancer treated with chemotherapy. One option for managing chemotherapy-induced anemia (CIA) is erythropoiesis-stimulating proteins (ESPs), which are indicated for the treatment of CIA in patients with most types of cancer. They have been shown to be safe and effective in numerous well-documented studies, and their side effects are well known. The rate of thrombotic events with the long-acting ESP darbepoetin alfa (Aranesp) has been consistent in studies conducted before and after its approval. The association of thrombotic events with high hemoglobin levels or rapid increases in its levels in patients with cancer remains controversial. Adjusting the dose of the ESP to maintain and monitor a target hemoglobin level of 11 to 12 g/dL is certainly prudent and may help prevent or minimize these events. Chemotherapy-induced anemia has been associated with shorter survival in patients with cancer, and the relation is likely multifactorial. Data on the treatment of CIA with ESPs have not shown a consistent effect on survival. Two studies in patients with hemoglobin levels above the target level showed that survival was shorter in the patients treated with ESPs. A review of data from other trials found no effect of ESPs on survival, and other trials suggested a positive effect. This article reviews data on survival in patients treated with ESPs and discusses five large randomized controlled trials of darbepoetin alfa that are addressing this issue.

Anemia↗

[The erythrokaryocyte, the reticulocyte, the normocyte: their place in the scheme of erythropoiesis].

Estimation of reticulocyte and polychromatophil counts has shown that only 28.7-44.9 percent of blood reticulocytes and 61.7 percent of bone marrow reticulocytes are polychromatophilic. Polychromatophil count is approximately equal to the sum of classes I and II reticulocytes. Bone marrow smears staining to detect reticulocytes, followed by staining according to Romanovsky-Giemsa has shown that only solitary erythrokaryocytes did not contain granular or filament reticular substance. The authors analyze the following suppositions: eliminate reticulocytes from the erythropoiesis scheme, denote the former normoblasts erythrokaryocytes but not normocytes, demonstrate the possibility of mature red cell production from oxyphilic erythrokaryocytes and from polychromophilic erythrokaryocytes via polychromatophilic red cells in the scheme.

Bone Marrow Cells↗

Erythropoiesis in Fanconi's anemia.

Fanconi's anemia (FA) is an autosomal recessive condition in which greater than 90% of the homozygotes develop aplastic anemia. To determine the relation between erythroid progenitors and clinical status, blood and marrow mononuclear cells were cultured in methyl cellulose with erythropoietin, plus other hematopoietic growth factors, and growth in normal oxygen (20%) was compared with growth in low, physiologic oxygen (5%). Peripheral blood cultures were performed from 24 patients, and marrows from six. Patients were classified into six clinical groups. Group 1: Severe aplasia, transfused; one patient; no erythroid progenitors. Group 2: Severe, transfused, androgen unresponsive; one patient; no blood burst-forming units-erythroid (BFU-E). Group 3: Androgen responsive; eight patients, with decreased blood BFU-E. Group 4: Aplastic, about to start treatment; two patients; below normal numbers of colony-forming units-erythroid (CFU-E) and BFU-E. Group 5: Stable, with mild anemia, and/or thrombocytopenia, and/or macrocytosis; seven patients; with below normal numbers of blood BFU-E. Group 6: Hematologically normal; five patients; blood BFU-E low normal to normal. One marrow had normal numbers of CFU-E and BFU-E. Incubation in 5% oxygen doubled CFU-E and BFU-E only in the patients with close to normal or normal growth in 20% oxygen. Hemin and interleukin-3 increased growth slightly in those cultures where there was some growth with erythropoietin alone. Our data show that there is a correlation between current clinical status and in vitro erythropoiesis. Cultures of erythroid progenitors may also be useful predictors of hematologic prognosis in FA, although our follow-up period is too short to prove this hypothesis.

Adolescent↗

[Expression and extracellular release of transferrin receptors on erythropoiesis].

One of the most important factors for the proliferation and hemoglobin synthesis of erythroid cells is iron atom. This atom is tightly bound to serum transferrin (Tf) and is taken up by erythroblasts and reticulocytes through transferrin receptor (TfR). Both Tf and TfR are reutilizable and have roles for the efficient intracellular accumulation of iron. In addition to the reutilization (recycling), the expression of TfR is also regulated by cytoplasmic iron concentration; the increase of iron downregulate the synthesis of TfR at the translational level and vice versa. This mechanism was recently explained by the binding between "iron responsive element (IRE)" in the 5' end of TfR mRNA and IRE binding protein by a transacting manner. Johnstone et al, and we found that TfR was externalized from sheep reticulocyte and human erythroleukemia cell, K562, respectively. Furthermore, we confirmed that this shed TfR was detected in blood and concluded that the quantitation of TfR in serum is a useful index for evaluating the erythropoiesis. The serum TfR was increased in iron deficiency anemia, hemolytic anemia and polycythemia and was decreased in aplastic anemia. In renal anemia, it was increased after the administration of erythropoietin (Epo). By the in vitro liquid culture of peripheral blood stem cells using interleukin 3 and Epo, it was found that soluble TfR was derived from the erythroblasts during the maturation process.

Cell Differentiation↗

[The role of the autonomic nervous system in regulating bone marrow erythropoiesis in stress].

Injection of one of the pharmacological neurotropic antagonists (neuroleptic, ganglionic blocking, alpha- or beta-adrenergic blocking agents) abolished the phenomenon of erythropoiesis activation in immobilization stress in mice. Blockade of alpha- and beta-adrenergic receptors significantly reduced the number of erythroid colonies forming from cells of bone marrow culture in vitro and the erythropoietin level in blood serum and supernatants of bone marrow cells. The M-cholinergic blocking agent had no effect on the bone marrow erythrokaryocyte content in immobilized animals. At the same time, stimulation of alpha- and beta-adrenergic receptors led to a dose-dependent increase of the number of erythroid cells in the bone marrow of mice exposed to the effect of immobilization.

Animals↗

Interrelationship between erythropoietin and erythropoiesis: insights from renal transplantation.

In successful renal transplant recipients, transient and modest increases in endogenous erythropoietin (Epo) reverse anemia, whereas in dialysis patients, sustained administration of large doses of exogenous Epo is required for the correction of uremic anemia. Moreover, in transplant recipients, serum Epo returns to normal as the hematocrit level increases to greater than 32%. Thereafter, the hematocrit continues to increase to normal levels, while serum Epo remains in the normal range. Thus, the restoration of renal function may improve the erythropoietic response to Epo, and/or erythropoiesis in transplant patients may be stimulated by factors other than, or in addition to, Epo. In early posttransplant patients who develop erythrocytosis, serum Epo levels are often elevated, while in long-term transplant recipients, erythrocytotic patients (with normal serum ferritin) have normal serum Epo levels. On the other hand, in long-term transplant recipients with low serum ferritin, circulating Epo levels are elevated, even in patients with no overt anemia. This suggests a possible interaction between body iron store status and the synthesis of Epo.

Anemia↗

[Regulation of erythropoiesis in patients with iron deficiency anemia].

Erythropoietin level in the blood plasma, iron metabolism, and some erythron parameters characterizing anemia expression, erythropoiesis effectiveness and processes of hemoglobin synthesis were studied in patients with iron-deficiency anemia (IDA). The results of the investigation helped the authors to establish that hormone production in IDA patients is under the control of a feedback mechanism that is functioning at a lower level as compared to other non-renal anemias. It has been suggested that optimum possible erythron functioning in IDA patients is achieved under these conditions.

Adolescent↗

The effect of 5-fluorouracil on erythropoiesis.

The effects of a single dose (150 mg/kg) of 5-fluorouracil on mature erythroid and erythropoietic and multipotential in vitro precursor populations in the bone marrow and spleen and circulating biologically (erythroid colony forming unit [CFU-E] assay) and immunologically active (enzyme-linked immunosorbent assay) erythropoietin (Epo) are described. All mature erythroid (reticulocytes, erythrocytes) and in vitro erythropoietic precursors (CFU-E, erythroid burst-forming unit [BFU-E]) are severely reduced, if not eradicated. Transient repopulation of the pure BFU-E and CFU-E populations on days 6 and 7, respectively, produces a marked reticulocytosis after day 9. Circulating Epo increases to above normal values by day 2. However, whereas biologically active Epo remains constant at this level until day 9, immunologically active Epo continually increases; by day 12, however, both assays detect circulating Epo levels of about 400 mU/mL. In vitro multipotential stem cells (BFU-E mix) are reduced to 32% on day 1, 7.6% on day 2, and return to normal values between days 4 and 5. The survival and repopulation kinetics of the BFU-E mix imply a stem cell population more mature than the high proliferative potential colony-forming cells. However, the BFU-E mix may be responsible for erythropoiesis repopulating ability.

Animals↗

Cell-cell interactions and erythropoiesis.

The erythroblastic island, a distinct anatomical unit consisting of a central macrophage surrounded by a ring of erythroblasts, is a key feature of erythropoiesis in the bone marrow. While a number of functional sequelae for the interaction between the erythroblasts and macrophage have been suggested, much remains to be learned. We suggest that this interaction may play a role in regulated assembly of membrane proteins during erythroid differentiation.

Cell Communication↗

Expression of dematin (protein 4.9) during avian erythropoiesis.

The expression of avian erythrocyte dematin (protein 4.9) was studied in short-term tissue culture and in vivo in chickens. Our results show that erythrocyte dematin consists of five immunoreactive variants of 44, 47, 49, 50, and 52 kDa which are differentially synthesized and accumulated during avian embryonic development. While synthesis of the 47 and 49 kDa forms of dematin is constitutive, the 44 kDa variant is synthesized primarily early during development (day 6), and the 50 and 52 kDa variants are synthesized at mid to late times (days 10-15). Short-term tissue culture experiments show that much of the 47 and 49 kDa forms of dematin synthesized in 5-day erythrocytes is degraded, whereas no degradation of newly synthesized polypeptides is detected later in development (mature, 20-day erythrocytes). Experiments performed in vivo are consistent with the observations in short-term tissue culture and demonstrate that the stable form of dematin is synthesized late in erythropoiesis during the reticulocyte stage. The accumulation of dematin and the timing of its assembly relative to beta-spectrin suggest a role for dematin in stabilizing the cytoskeleton of the terminally differentiated erythrocyte.

Animals↗

Patterns of erythropoiesis and anaemia in malaria.

Of 138 patients with malaria, 90 were found to be having Plasmodium falciparum in their peripheral blood smears. Megaloblastosis alone or in combination with the other patterns of erythropoiesis was observed in 82.1 percent cases of chronic P. falciparum malaria as compared to 36.3 and 26.5 per cent cases of acute P. falciparum and P. vivax malaria respectively. Iron deficiency was observed in 15.5 percent cases of chronic P. falciparum, 18.2 per cent cases of acute P. falciparum and 13.3 per cent patients of P. vivax infection. Of patients with chronic falciparum malaria, 33.3 percent revealed features of both megaloblastosis and defective iron utilization and transient hypoplasia of marrow was observed in 8.9 per cent of these cases.

Adolescent↗